Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725667 | 1.00 | KMT2A (0.73) | KMT2AL3MBTL1MEN1CXCR6LTA4H | |
| SCHEMBL3880814 | 0.90 | KMT2A (0.61) | KMT2AL3MBTL1MEN1CXCR6LTA4H | |
| SCHEMBL3880817 | 0.90 | KMT2A (0.61) | KMT2AL3MBTL1MEN1CXCR6LTA4H | |
| SCHEMBL4855029 | 0.89 | KMT2A (0.71) | KMT2AL3MBTL1MEN1LTA4HMAPT | |
| SCHEMBL1851171 | 0.89 | KMT2A (0.91) | KMT2AL3MBTL1MEN1OPRK1USP2 | |
| SCHEMBL29725634 | 0.88 | KMT2A (0.72) | KMT2AL3MBTL1MEN1CXCR6MAPT | |
| SCHEMBL20967988 | 0.84 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1USP2 | |
| SCHEMBL29410965 | 0.84 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1USP2 | |
| SCHEMBL4794886 | 0.84 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1USP2 | |
| SCHEMBL4859779 | 0.82 | KMT2A (0.65) | KMT2AL3MBTL1MEN1CXCR6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376818-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2023-03-09 | — | — | US | disclosed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR1A | KMT2A 3310/4885L3MBTL1 2519/4885MEN1 143/4885 |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR1A | KMT2A 3310/4885L3MBTL1 2519/4885MEN1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.